Coherent Market Insights published a business research report on Histone Deacetylase Inhibitors Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2022–2028. Histone Deacetylase Inhibitors Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/2686
Histone deacetylases (HDAC) are enzymes that remove the acetyl group from histone proteins on DNA, making the DNA less accessible to transcription factors. This in turn allows histones to wrap the DNA more tightly. This is important because DNA is wrapped around histones, and DNA expression is controlled by acetylation and de-acetylation. Mutations and aberrations induced into histone deacetylases are known to develop chronic diseases such as osteoporosis, cancer, cardiovascular diseases, inflammatory diseases, & neurodegenerative diseases, among others. In humans, there are around 18 HDACs, which are categorized into four classes, such as HDAC I, II (A and B), III, and IV.
Increasing research and development activities are expected to boost the growth of the global histone deacetylase inhibitors market during the forecast period. For instance, in May 2018, Syndax Pharmaceuticals and EddingPharm Oncology Co. initiated a study on the combination of exemestane and entinostat to treat advanced breast cancer in Chinese patients. Exemestane helps lower the level of estrogen and entinostat helps enhance anti-tumor effect of exemestane.
Moreover, in June 2016, The Netherlands Cancer Institute began a clinical trial of a medicine vorinostat to treat skin neoplasms. A clinical trial will evaluate safety and efficacy of the drug. Currently, it is in the second phase of clinical trial.
Moreover, frequent approvals of novel products by regulatory bodies is expected to augment the growth of the global histone deacetylase inhibitors market. For instance, in February 2015, the U.S. Food and Drug Administration (FDA) approved Novartis’s multiple myeloma drug Farydak. It is approved for the treatment in combination with dexamethasone and bortezomib.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/2686
- Zolinza (Vorinostat)
- Istodax (Romidepsin)
- Beleodaq (Belinostat)
- Farydak (Panabinostat)
By Distribution Channel:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Side effects associated with HDAC inhibitors is expected to hinder growth of the global histone deacetylase inhibitors market. HDAC inhibitors, such as Farydak, can have side effects such as fatal cardiac events, severe diarrhea, and arrhythmia while Zolinza can cause swelling on lip, face, etc., clotting of blood in legs or lungs, and sometimes difficulty in breathing.
North America is expected to witness robust growth in the global histone deacetylase inhibitors market due to the increasing prevalence of cancer in the region. For instance, as per the National Institutes of Health (NIH), more than 439.2 (per 100,000 men and women) cancer cases were found in the United States between 2011 and 2015.
Major players active in the global histone deacetylase inhibitors market are Merck & Co. Inc., Novartis AG, Celgene Corp., AbbVie Inc, and Acrotech Biopharma LLC, among others.
Buy This Report With USD 2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2686
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Histone Deacetylase Inhibitors Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Histone Deacetylase Inhibitors Industry Impact
Chapter 2 Global Histone Deacetylase Inhibitors Competition by Types, Applications, and Top Regions and Countries
2.1 Global Histone Deacetylase Inhibitors (Volume and Value) by Type
2.3 Global Histone Deacetylase Inhibitors (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Histone Deacetylase Inhibitors Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Histone Deacetylase Inhibitors Market Analysis
Chapter 6 East Asia Histone Deacetylase Inhibitors Market Analysis
Chapter 7 Europe Histone Deacetylase Inhibitors Market Analysis
Chapter 8 South Asia Histone Deacetylase Inhibitors Market Analysis
Chapter 9 Southeast Asia Histone Deacetylase Inhibitors Market Analysis
Chapter 10 Middle East Histone Deacetylase Inhibitors Market Analysis
Chapter 11 Africa Histone Deacetylase Inhibitors Market Analysis
Chapter 12 Oceania Histone Deacetylase Inhibitors Market Analysis
Chapter 13 South America Histone Deacetylase Inhibitors Market Analysis
Chapter 14 Company Profiles and Key Figures in Histone Deacetylase Inhibitors Business
Chapter 15 Global Histone Deacetylase Inhibitors Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027